Frontline Therapy Decisions: NALIRIFOZ, FOLFIRINOX, and Practical Management

15 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
YouTube Description
In this community oncology discussion, Dr. Rohit Gosain is joined by Dr. Raji Shameem (Orlando Health) to break down first-line treatment decisions for metastatic pancreatic adenocarcinoma when no actionable biomarkers are found. They delve into the practical choice between NALIRIFOX, modified FOLFIRINOX, and gemcitabine-paclitaxel, emphasizing the importance of picking the most effective regimen first. Dr. Shameem highlights the survival benefit and structured dosing guidelines from the NAPOLI 3 trial, offering key insights on managing side effects like diarrhea and the role of upfront UGT1A1/DPD testing.

This conversation provides essential clinical pearls for community oncologists navigating treatment selection, dose modification, and patient communication in metastatic pancreatic cancer.

Website: https://oncupdates.com/
Mail: [email protected]
X/twitter: https://x.com/OncUpdates

#PancreaticCancer #CommunityOncology #NALIRIFOX #FOLFIRINOX #MedicalOncology #CancerTreatment
Categoria
Oncology
Commenta per primo questo video.

Prossimo